LT2330892T - Methods of treatment using ammonia-scavenging drugs - Google Patents

Methods of treatment using ammonia-scavenging drugs

Info

Publication number
LT2330892T
LT2330892T LTEP09739263.3T LT09739263T LT2330892T LT 2330892 T LT2330892 T LT 2330892T LT 09739263 T LT09739263 T LT 09739263T LT 2330892 T LT2330892 T LT 2330892T
Authority
LT
Lithuania
Prior art keywords
ammonia
treatment
methods
scavenging drugs
scavenging
Prior art date
Application number
LTEP09739263.3T
Other languages
Lithuanian (lt)
Inventor
Bruce Scharschmidt
Original Assignee
Horizon Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Therapeutics, Inc. filed Critical Horizon Therapeutics, Inc.
Priority claimed from PCT/US2009/030362 external-priority patent/WO2009134460A1/en
Publication of LT2330892T publication Critical patent/LT2330892T/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
LTEP09739263.3T 2008-08-29 2009-01-07 Methods of treatment using ammonia-scavenging drugs LT2330892T (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9323408P 2008-08-29 2008-08-29
PCT/US2009/030362 WO2009134460A1 (en) 2008-04-29 2009-01-07 Methods of treatment using ammonia-scavenging drugs

Publications (1)

Publication Number Publication Date
LT2330892T true LT2330892T (en) 2016-11-25

Family

ID=45604478

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP09739263.3T LT2330892T (en) 2008-08-29 2009-01-07 Methods of treatment using ammonia-scavenging drugs
LTEP16176456.8T LT3133396T (en) 2008-08-29 2009-01-07 Methods of treatment using ammonia-scavenging drugs

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP16176456.8T LT3133396T (en) 2008-08-29 2009-01-07 Methods of treatment using ammonia-scavenging drugs

Country Status (10)

Country Link
JP (3) JP5577341B2 (en)
DK (1) DK3133396T3 (en)
ES (2) ES2695534T3 (en)
HR (2) HRP20161222T1 (en)
HU (2) HUE040503T2 (en)
LT (2) LT2330892T (en)
PL (1) PL2330892T3 (en)
PT (2) PT3133396T (en)
SI (1) SI3133396T1 (en)
TR (1) TR201816616T4 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2629859T3 (en) 2011-09-30 2017-08-16 Horizon Therapeutics, Llc Drugs to remove nitrogen for use in a procedure to treat a nitrogen retention disorder
CN104540507A (en) * 2012-04-20 2015-04-22 海波龙治疗公司 Methods of therapeutic monitoring of phenylacetic acid prodrugs
LT2922576T (en) * 2012-11-21 2018-02-12 Horizon Therapeutics, Llc Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
US20220044801A1 (en) * 2018-10-04 2022-02-10 Atonarp Inc. Living body information acquisition system, health management server, and system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) * 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
DE69612755T2 (en) * 1995-02-07 2001-08-23 Brusilow Entpr Llc TRIGLYCERIDES AND ETHYLESTERS OF PHENYLALKOIC ACIDS AND PHENYLALKOIC ACIDS FOR THE TREATMENT OF VARIOUS DISEASES
US20070004805A1 (en) * 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate

Also Published As

Publication number Publication date
JP2012501451A (en) 2012-01-19
JP5577341B2 (en) 2014-08-20
PT2330892T (en) 2016-09-05
LT3133396T (en) 2018-11-26
TR201816616T4 (en) 2018-11-21
JP2012501329A (en) 2012-01-19
HRP20181877T1 (en) 2019-01-11
ES2593378T3 (en) 2016-12-09
DK3133396T3 (en) 2018-12-03
ES2695534T3 (en) 2019-01-08
HUE029912T2 (en) 2017-03-28
SI3133396T1 (en) 2018-12-31
HUE040503T2 (en) 2019-03-28
HRP20161222T1 (en) 2017-02-10
PT3133396T (en) 2018-12-07
PL2330892T3 (en) 2017-05-31
JP2014102255A (en) 2014-06-05

Similar Documents

Publication Publication Date Title
HUS1600057I1 (en) Methods of treatment using ammonia-scavenging drugs
IL208354A0 (en) Methods of treatment
HK1169804A1 (en) Methods for treatment of pain
ZA201106730B (en) Methods of treatment using combination therapy
EP2300011A4 (en) Therapeutic methods and compounds
HRP20181877T1 (en) Methods of treatment using ammonia-scavenging drugs
HUS1600039I1 (en) Methods of treatment using single doses of oritavancin
EP2350641A4 (en) Method of treatment
EP2387418A4 (en) Pain treatment
EP2164494A4 (en) Methods of treatment
GB0723100D0 (en) Treatment of HFnEF
HK1131039A1 (en) Pharmaceutical use of sophoricoside
GB2460445B (en) Treatment of ringworm
SI2330892T1 (en) Methods of treatment using ammonia-scavenging drugs
EP2440238A4 (en) Methods of treatment
EP2203432A4 (en) Method of treatment
GB0700969D0 (en) Methods of treatment
GB0817859D0 (en) Treatment of proteostatic disease
GB0819543D0 (en) Treatment of proteostatic disease
GB0823435D0 (en) Method of treatment
GB0717337D0 (en) Method of treatment
GB0803515D0 (en) Medicament and method of treatment
AU2008902372A0 (en) Methods of treatment
GB0720136D0 (en) Treatment of blood disorded
GB0804468D0 (en) Treatment of influenza